Barclays
ALXO icon

Barclays’s ALX Oncology ALXO Stock Holding History

Barclays’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.1K Hold
10,515
– – ﹤0.01% 4568
2025
Q4 		$11.9K Sell
10,515
-52
-0.5% -$79 ﹤0.01% 4918
2025
Q3 		$19.3K Hold
10,567
– – ﹤0.01% 4939
2025
Q2 		$4.39K Sell
10,567
-37,462
-78% -$18.9K ﹤0.01% 4987
2025
Q1 		$29.9K Sell
48,029
-17,093
-26% -$20.5K ﹤0.01% 4724
2024
Q4 		$109K Buy
65,122
+5,620
+9% +$8.64K ﹤0.01% 4575
2024
Q3 		$108K Buy
59,502
+42,185
+244% +$157K ﹤0.01% 4553
2024
Q2 		$104K Sell
17,317
-11,318
-40% -$139K ﹤0.01% 3884
2024
Q1 		$319K Sell
28,635
-16,002
-36% -$225K ﹤0.01% 3853
2023
Q4 		$665K Buy
44,637
+17,673
+66% +$168K ﹤0.01% 3705
2023
Q3 		$129K Buy
26,964
+9,796
+57% +$53.2K ﹤0.01% 3495
2023
Q2 		$129K Buy
17,168
+1,621
+10% +$10.6K ﹤0.01% 3462
2023
Q1 		$70.3K Buy
15,547
+4,019
+35% +$30.4K ﹤0.01% 4338
2022
Q4 		$130K Buy
11,528
+4,851
+73% +$54.5K ﹤0.01% 4078
2022
Q3 		$64K Buy
6,677
+2,464
+58% +$28.7K ﹤0.01% 3700
2022
Q2 		$34K Sell
4,213
-494
-10% -$5.38K ﹤0.01% 4189
2022
Q1 		$80K Buy
+4,707
New +$80.4K ﹤0.01% 3889

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Barclays's ALXO Position: Q1 2026 in Review

Barclays held its ALX Oncology (ALXO) position steady in Q1 2026 at 10,515 shares worth $21.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4568.

Barclays first reported a position in ALXO in Q1 2022 and has held it in 17 quarters since. The position peaked at $665K in Q4 2023. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Barclays held 10,515 shares of ALX Oncology worth $21.1K as of Q1 2026.
  • Barclays left its ALX Oncology share count unchanged in Q1 2026.
  • ALX Oncology made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4568 holding.
  • Barclays first reported a position in ALX Oncology in Q1 2022 and has held it in 17 quarters since.
  • Barclays's ALX Oncology position peaked at $665K in Q4 2023.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.